Increased expression of microRNA-26a-5p predicted a poor survival outcome in osteosarcoma patients

An observational study

Xiao-Yu Xie, MD, Xian-Ming Chen, MD, Ling Shi, MD, Jun-Wei Liu, MD

Abstract

MicroRNA (miR)-26a-5p is an oncogene significantly associated with osteosarcoma. We try to evaluate expression of circulating miR-26a-5p in osteosarcoma patients and evaluate its significance.

A total of 243 consecutive osteosarcoma patients and 96 healthy participants were enrolled. Circulating miR-26a-5p levels were evaluated by using real-time quantitative reverse transcription polymerase chain reactions (RT-PCR). The association between circulating miR-26a-5p level and survival outcomes was evaluated by univariate and multivariate analysis.

Circulating miR-26a-5p levels in osteosarcoma patients was significantly higher than that of healthy volunteers ($P < .05$). Upregulated miR-26a-5p was significantly related to advanced cancer and metastasis (both $P < .05$). Moreover, patients with a high serum miR-26a-5p had a poorer overall survival than those with a low serum miR-26a-5p levels ($P < .05$). Circulating miR-26a-5p level also been showed as independent risk factor for osteosarcoma in multivariate analysis (hazard ratio [HR], 0.38; 95% confidence interval [CI]: $0.11–0.98$; $P < .01$).

Circulating miR-26a-5p was significantly upregulated in osteosarcoma patients and remarkably associated with poor prognosis, indicating that circulating miR-26a-5p might serve as a useful diagnostic and prognostic biomarker for osteosarcoma.

Abbreviations: AUC = area under the curve, MiR = MicroRNA, OS = overall survival, RFS = recurrence-free survival, ROC = receiver operating characteristic curve, RT-PCR = real-time quantitative reverse transcription polymerase chain reactions.

Keywords: osteosarcoma, prognosis, serum miR-26a-5p

1. Introduction

Osteosarcoma is the most frequent malignant primary sarcoma and the second contributor of cancer related mortality among adolescents.[1,2] Moreover, most of osteosarcoma cases are confirmed at advanced stage, with a very poor prognosis.[3,4] Although considerable advancement of diagnostic strategies, surgery and adjuvant treatments during past decades, the long-term prognosis of osteosarcoma patients remains unsatisfactory. Early lung metastasis and recurrences were considered as main contributors of poor prognosis of osteosarcoma.[5,6] In details, recurrences could be observed in approximately 60% to 80% of osteosarcoma patients received surgery, with a postoperative 5-year survival rate of 15% to 20%.[7] However, the unclear potential molecular mechanisms underlying the histological heterogeneity, poor treatments response, and recurrent were still bothering orthopedic surgeons. Therefore, furtherly exploring of molecular mechanisms associated with the development, progression, and aggressiveness of osteosarcoma is curial for diagnosis, risk stratification, and individual treatment for osteosarcoma patients.

MicroRNAs (miRNAs) is a novel subset of endogenous small non-coding RNAs, which can specifically regulate post-transcriptional gene expression by inhibiting the translation and/or decreasing of the stability of specific protein-coding gene.[8] Previous studies showed that dysregulated expression of miRNAs was commonly observed in development of several malignancies.[9-11] It has been showed that miRNAs can be stably expressed in plasma with an appropriate and measurable
concentration.\textsuperscript{12,13} Furthermore, various circulating miRNAs have been evaluated as valuable noninvasive biomarkers for cancers.\textsuperscript{14,15} MicroRNA-26a-5p (miR-26a-5p), a tumor-associated miR, has been found to be implicated in the development of various cancers by regulating tumor cell proliferation, invasion, migration, and apoptosis.\textsuperscript{16} Shi et al.\textsuperscript{17} found that miR-26a-5p inhibits proliferation, invasion, and metastasis by repressing the expression of Wnt5a in papillary thyroid carcinoma. Huang et al.\textsuperscript{18} found that miR-26a-5p inhibits breast cancer cell growth by suppressing RNF6 expression. Moreover, miR-26a-5p has been confirmed to act as a tumor oncogene for osteosarcoma in vitro and in vivo experiments, which can promote proliferation and migration of osteosarcoma by targeting HOXAS.\textsuperscript{19} However, no evidence regarding the value of circulating miR-26a-5p in osteosarcoma has been reported. Therefore, in present study, we try to evaluate expression level of circulating miRNA-26a-5p in osteosarcoma patients and analyze its prognostic value.

2. Materials and methods

2.1. Patients

This study protocol was planned by basing on the relevant guidelines or regulations and conformed to the Declaration of Helsinki. All subjects have provided signed informed consent prior to enrollment. This study was also approved by the Research Ethics Committee of the Daping Hospital, Army Medical University. Total of 243 patients with primary localized osteosarcoma admitted to Department of Orthopaedic Surgery between July 1, 2015 and July 1, 2018 were retrospectively collected. All enrolled patients were diagnosed as osteosarcoma by pathology evaluation. Exclusion was conducted based on following criteria: preoperative comorbidity, relapse and metastasis, incomplete clinical and histopathological data, and life expectancy <4 months. All enrolled patients received neo-adjuvant chemotherapy (combination of doxorubicin and methotrexate), surgical resection, and postoperative chemotherapy according to the 2018 European Sarcoma Network Working Group Clinical Practice Guidelines for osteosarcoma.\textsuperscript{20} Total of 96 age and sex-matched healthy participants were recruited as the control group.

All relevant clinical and pathological data of each patient was collected and reconfirmed. The clinical stages were evaluated according to the system for the surgical staging of musculoskeletal sarcoma. All enrolled patients were regularly followed up by outpatient visiting or telephone. Follow-up was ended at June 2019. The median follow-up time was 26.3 months. The primary outcome of interest was survival status. Overall survival (OS) was defined as the interval from the date of enrollment to the date of death or endpoint. Recurrence-free survival (RFS) was defined as from the date of curative treatment to the date of tumor recurrence or last known date alive.

2.2. RNA isolation and quantitative real-time PCR

Total RNA was extracted from 400 mL of serum by using TRIzol Reagent (Invitrogen, Mulgrave, Australia) in accordance with the manufacturer’s instructions. The TaqMan miRNA assay kit (Applied Biosystems, Foster City, CA) was used to quantitatively assess the expression levels of miR-26a-5p. LightCycler480 system (Roche, Mannheim, Germany) was used to perform Real-Time PCR with a SYBR Premix Ex TaqTM (Takara, Dalian, China) according to the manufacturer’s instructions. U6 was chosen as the reference gene for normalization. The $2^{-\Delta \Delta Ct}$ method was applied to evaluate the relative expression levels of miR-26a-5p. Each sample was measured in triplicate. The primer sequences used in present study were as follows: miR-26a-5p-forward: 5'-UCCAUAAAAGAGAAGACUCA-3', backward: 5'-CAGUACUUUUGUAGUACAA-3'; U6-forward: 5'-CTCGCTTCGCACGACCATAC-3', backward: 5'-ACGCTCACGAAATTGCGTGC-3'.\textsuperscript{19}

2.3. Statistical analysis

Statistical analysis was carried out by using the SPSS 20.0 statistical package (IBM, USA). The statistical results were considered as significant while $P<.05$ (2 sided). Continuous variables that expressed as mean ± SD were compared by using analysis of variance (ANOVA), whereas comparisons of categorical variables were conducted by using chi-square or Fisher exact test, which were presented as frequencies (%). Receiver operating characteristic curve (ROC) analysis was performed to evaluate the prognostic and diagnostic value of circulating miR-26a-5p levels. Kaplan–Meier survival curves for circulating miRNA-26a-5p levels predicting survival were analyzed by log-rank test. Univariate and multivariate Cox hazard regression model was employed to evaluate the prognostic factors for osteosarcoma.

3. Results

3.1. Circulating miR-26a-5p expression in patients with osteosarcoma

Circulating miR-26a-5p level was significantly upregulated in osteosarcoma patients compared with the healthy subjects ($P<.05$, see Fig. 1A). Furthermore, ROC curve analysis demonstrated that circulating miR-26a-5p level could be used as a promising biomarker for distinguishing osteosarcoma patients from healthy subjects, with an area under the curve (AUC) of 0.76 (95% CI: 0.64–0.81), a sensitivity of 69.7% and a specificity of 74.3% ($P<.05$, Fig. 1B).

3.2. Association of circulating miR-26a-5p and clinicalopathological characteristics

All 243 osteosarcoma patients were divided into a high miR-26a-5p group (n = 126) or a low miR-26a-5p group (n = 117) by using the median value of serum miR-26a-5p level as the cut-off point. As showed in Table 1, a high serum miR-26a-5p levels was significantly associated with distance metastasis and advanced clinical stage (both $P<.01$, Table 1). However, other clinical variables, including age, sex, tumor site and size, and pathology were not closely associated with serum miR-26a-5p expression (all $P>.05$). (Table 1).

3.3. Prognostic significance of circulating miR-26a-5p level in osteosarcoma patients

According to the results of Kaplan–Meier method and log-rank test, patients with an upregulated expression of circulating miR-26a-5p had a significantly poorer OS than those with a low expression of miR-26a-5p ($P=.02$, Fig. 2). Moreover, a higher circulating miR-26a-5p level was also significantly associated a poorer RFS ($P=.04$, Fig. 3).
The univariate and multivariate analysis enrolled age and sex of patients, tumor size, distant metastasis, clinical stage, histological type and circulating miR-26a-5p level to determine independent prognostic indicator for osteosarcoma patients. After adjustment for potential confounders, an upregulated circulating miR-26a-5p (hazard ratio [HR], 0.38; 95% confidence interval [CI]: 0.11–0.98, \( P < .01 \)) was also an independent risk factor for survival outcome of osteosarcoma patients (Table 2).

### 4. Discussion

In this study, we demonstrated that circulating miR-26a-5p was significantly upregulated in osteosarcoma patients comparing with healthy participates. Moreover, circulating miR-26a-5p level can be used as a compromising diagnostic biomarker discriminating osteosarcoma patients from healthy subjects. Furthermore, we evaluated the ability of circulating miR-26a-5p in predicting prognosis of osteosarcoma patients, and found that a high circulating miR-26a-5p level was significantly associated with poorer survival in osteosarcoma patients. We also observed an obvious association between circulating miR-26a-5p level and classical unfavorable prognostic markers for osteosarcoma patients. Based on these results, we suggested that miR-26a-5p can be used as a diagnostic biomarker for osteosarcoma patients, which also can serve as a promising prognostic biomarker.

### Table 1

**Correlation between serum miR-217 level and clinicopathologic characteristics of osteosarcoma patients.**

| Characteristic   | Serum miR-217 | High (n = 77) | Low (n = 86) | \( P \) |
|------------------|---------------|---------------|--------------|--------|
| Age, y           |               | .63           |              |        |
| ≥25              | 36            | 37            |              |        |
| <25              | 41            | 49            |              |        |
| Gender           |               | .26           |              |        |
| Male             | 54            | 67            |              |        |
| Female           | 23            | 19            |              |        |
| Tumor site       |               | .48           |              |        |
| Tibia/femur      | 46            | 56            |              |        |
| Other            | 31            | 30            |              |        |
| Tumor size, cm   |               | .90           |              |        |
| ≥8               | 33            | 36            |              |        |
| <8               | 44            | 50            |              |        |
| Distant metastasis|              | <.01          |              |        |
| Yes              | 18            | 54            |              |        |
| No               | 59            | 32            |              |        |
| Clinical stage   |               | <.01          |              |        |
| IIA              | 54            | 16            |              |        |
| IIB+III          | 23            | 70            |              |        |
| Pathology        |               | .10           |              |        |
| Osteogenic or chondrocytic | 46    | 62            |              |        |
| Fibrocytic or mixed | 31     | 24            |              |        |
MiR-26a-5p, as a novel tumor biomarker, plays critical roles in the biological process of cancer development.\(^{21,22}\) The miR-26a-5p has been confirmed as a potential oncoprobe in many malignancies including osteosarcoma.\(^{23,24}\) Song et al\(^{24}\) showed that miR-26a-5p potentiated lung cancer cell metastasis via JAK2/STAT3 pathway by targeting ITGa.\(^2\) In this study, we also found that low serum level of miR-26a-5p was remarkably associated with advanced cancer patients. It has been reported that low expressions of certain miRNAs were remarkable associated with poor prognosis, which are consistent with the previous studies mentioned above.

However, the underlying function and origin of serum miR-26a-5p in malignancy have not yet been fully understood. Several potential mechanisms for circulating miRNAs releasing have been reported, including passive leakage from cells in setting of chronic inflammation or injury, active secretion, complex formation with lipoproteins or RNA binding proteins.\(^{25}\) Wang et al\(^{23}\) reported that highly expressed miR-26a-5p in osteosarcoma cells and promotes proliferation and migration by targeting HOXA5. In our study, miR-26a-5p was remarkably upregulated in osteosarcoma proliferation and migration by targeting HOXA5. In our study, miR-26a-5p was remarkably upregulated in osteosarcoma growth and development.

Several limitations in this study. One limitation was a single center, small sample size, and retrospective design of study. A large-scale, prospective, and multicenter study is required to furtherly reevaluate such results. Furthermore, the underlying roles and mechanisms of miR-26a-5p in development of osteosarcoma have not yet been fully evaluated. Future experiments need to be performed to elucidate the mechanisms of circulating miR-26a-5p in carcinogenesis.

5. Conclusions

In this study, we found that circulating miR-26a-5p levels were upregulated in osteosarcoma patients. Moreover, upregulated circulating miR-26a-5p level was significantly associated with poor survival of osteosarcoma patients, indicating that miR-26a-5p might not only serve as a diagnostic and prognostic biomarker for osteosarcoma, but also a potential novel treatment target.

Author contributions

Conceptualization: Xiao-Yu Xie, Junwei Liu.
Data curation: Xiao-Yu Xie, Xian-Ming Chen.
Formal analysis: Xiao-Yu Xie, Junwei Liu.
Funding acquisition: Xian-Ming Chen, Junwei Liu.
Investigation: Xian-Ming Chen.
Methodology: Xiao-Yu Xie, Xian-Ming Chen.
Project administration: Xian-Ming Chen, Ling Shi.
Resources: Xian-Ming Chen, Ling Shi, Junwei Liu.
Software: Xian-Ming Chen.
Supervision: Ling Shi, Junwei Liu.
Validation: Ling Shi, Junwei Liu.
Visualization: Xiao-Yu Xie, Ling Shi.
Writing – original draft: Xiao-Yu Xie.
Writing – review & editing: Xiao-Yu Xie, Junwei Liu.

References

[1] Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009;125:229–34.
[2] Nie Z, Peng H. Osteosarcoma in patients below 25years of age: an observational study of incidence, metastasis, treatment and outcomes. Oncol Lett 2018;16:6902–14.
[3] Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;11:1531–43.
[4] Berner K, Johannesen TB, Berner A, et al. Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. Acta Oncol 2015;54:25–33.
[5] Sampo M, Kovikko M, Taskinen M, et al. Incidence, epidemiology and treatment results of osteosarcoma in Finland - a nationwide population-based study. Acta Oncol 2011;50:1216–14.
[6] Moreno F, Cacciavillano W, Cipolla M, et al. Childhood osteosarcoma: incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000-2013. Pediatr Blood Cancer 2017;64.
[7] Ronchi L, Buwenge M, Cortesi A, et al. Whole lung irradiation in patients with osteosarcoma and ewing sarcoma. Anticancer Res 2018;38:4977–85.
[8] Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis 2015;35:3–11.
[9] Tan T, Xu XH, Lu XH, et al. MiRNA-200a-3p suppresses the proliferation, migration and invasion of non-small cell lung cancer through targeting IRS2. Eur Rev Med Pharmacol Sci 2020;24:712–20.
[10] Tlusty MA, Nassar F, Sellam LS, et al. miRNA expression in advanced Algerian breast cancer tissues. PLoS One 2020;15:e0227928.
[11] Wang X, Ding Y, Wang L, et al. Identification of the key factors related to bladder cancer by lncRNA-miRNA-mRNA three-layer network. Front Genet 2019;10:1398.
[12] Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513–8.
[13] Ichikawa D, Komatsu S, Konishi H, et al. Circulating microRNA in digestive tract cancers. Gastroenterology 2012;142:1074.e1–8.e1.
[14] Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010;101:2087–92.
[15] Zhang J, Wang T, Zhang Y, et al. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients. Cancer Biomark 2018;21:763–8.
[16] Dong G, Zhang R, Xu J, et al. Association between microRNA polymorphisms and papillary thyroid cancer susceptibility. Int J Clin Exp Pathol 2015;8:13430–7.
[17] Shi D, Wang H, Ding M, et al. MicroRNA-26a-5p inhibits proliferation, invasion and metastasis by repressing the expression of Wnt5a in papillary thyroid carcinoma. Onco Targets Ther 2019;12:6605–16.
[18] Huang ZM, Ge HF, Yang CC, et al. MicroRNA-26a-5p inhibits breast cancer cell growth by suppressing RNF6 expression. Kaohsiung J Med Sci 2019;35:467–73.
[19] Yu T, Chen D, Zhang L, et al. microRNA-26a-5p promotes proliferation and migration of osteosarcoma cells by targeting HOXA5 in vitro and in vivo. Onco Targets Ther 2019;12:11555–65.
[20] Casali PG, Biedlack S, Abecasis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:v79–95.
[21] Zhu X, Yang G, Xu J, et al. Silencing of SNHG6 induced cell autophagy by targeting miR-26a-5p/ULK1 signaling pathway in human osteosarcoma. Cancer Cell Int 2019;19:82.
[22] Wang X, Lan Z, He J, et al. lncRNA SNHG6 promotes chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in colorectal cancer cells. Cancer Cell Int 2019;19:234.
[23] Wang H, Hu Z, Chen L. Enhanced plasma miR-26a-5p promotes the progression of bladder cancer via targeting PTEN. Onco Lett 2018;16:4223–8.
[24] Song Q, Liu B, Li X, et al. MiR-26a-5p potentiates metastasis of human lung cancer cells by regulating ITGbeta8– JAK2/STAT3 axis. Biochem Biophys Res Commun 2018;501:494–500.
[25] Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997–1006.
[26] Wang K, Zhang S, Weber J, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010;38:7248–59.
[27] Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009;2:ra81.
[28] Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev 2015;81:75–93.